Ipsen Teams Up with Foreseen Biotechnology to Develop FS001 for Solid Tumors
Shots:
- Ipsen & Foreseen have entered into an exclusive global licensing agreement through which the former receives exclusive worldwide rights for the development of FS001
- Under the agreement, Ipsen will handle P-I related events incl. IND submission, development, manufacturing & global commercialization. Foreseen will obtain upfront, development, regulatory & commercial milestones plus tiered royalties for a total of $1.03B
- FS001 is a FIC ADC comprising of an antibody and a linker-payload combined with a potent topoisomerase I inhibitor that depicted effectiveness & favorable safety in non-clinical studies. It is under final stages of the preclinical study
Ref: Ipsen | Image: Ipsen
Related News:- Ipsen Reports Collaboration Expansion with Exelixis to Develop Cabometyx for Treating Neuroendocrine Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
